Exelixis
EXEL
#2109
Rank
C$10.22 B
Marketcap
$35.84
Share price
-1.53%
Change (1 day)
23.67%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of June 2024 : C$0.26 B

According to Exelixis's latest financial reports the company's total debt is C$0.26 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31C$0.25 B-2.37%
2022-12-31C$0.25 B297.68%
2021-12-31C$64.88 M3.66%
2020-12-31C$62.59 M0.57%
2019-12-31C$62.23 M205.88%
2018-12-31C$20.34 M8.34%
2017-12-31C$18.78 M-92.61%
2016-12-31C$0.25 B-56.21%
2015-12-31C$0.58 B40.18%
2014-12-31C$0.41 B12.08%
2013-12-31C$0.36 B10.4%
2012-12-31C$0.33 B81.23%
2011-12-31C$0.18 B-11.51%
2010-12-31C$0.20 B148.77%
2009-12-31C$83.87 M-41.67%
2008-12-31C$0.14 B20.69%
2007-12-31C$0.11 B-15.89%
2006-12-31C$0.14 B-18.27%
2005-12-31C$0.17 B7.78%
2004-12-31C$0.16 B10.42%
2003-12-31C$0.14 B24.7%
2002-12-31C$0.11 B49.77%
2001-12-31C$77.96 M248.1%
2000-12-31C$22.39 M16.76%
1999-12-31C$19.18 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
C$29.07 B 10,725.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$34.53 B 12,757.84%๐Ÿ‡ซ๐Ÿ‡ท France
C$51.25 B 18,983.21%๐Ÿ‡บ๐Ÿ‡ธ USA
C$73.25 B 27,172.41%๐Ÿ‡บ๐Ÿ‡ธ USA
C$84.97 B 31,536.17%๐Ÿ‡บ๐Ÿ‡ธ USA
C$56.27 B 20,853.25%๐Ÿ‡บ๐Ÿ‡ธ USA
C$93.15 B 34,582.38%๐Ÿ‡บ๐Ÿ‡ธ USA
C$4.82 M-98.20%๐Ÿ‡บ๐Ÿ‡ธ USA
C$52.46 M-80.47%๐Ÿ‡บ๐Ÿ‡ธ USA